Skip to main content
TMDX
NASDAQ Industrial Applications And Services

TransMedics Q3 Revenue Jumps 41% to $203M, Full-Year Guidance Raised to $764-$774M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$76.8
Mkt Cap
$2.392B
52W Low
$60.105
52W High
$156
52W Position info
28% above low
Off High info
51% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

TMDX sits 28% above its 52-week low of $60.105 on elevated volume (1.8× avg).

Summary

TransMedics posted record Q3 revenue of $203.0 million, up 41%, with net income of $17.1 million, and raised full-year 2026 revenue guidance to $764-$774 million. Diluted EPS still fell to $0.46 from $0.66 as trial and expansion spending rose.


Key Events · Earnings and Guidance · TMDX

  • Record Q3 Revenue of $203M

    Total revenue rose 41% to $203.0 million from $143.8 million, with organic growth of 35% after excluding $9.4 million of PAD Aviation charter revenue.

  • Net Income Back to $17.1M

    Net income was $17.1 million, or $0.46 per diluted share, versus $24.3 million, or $0.66, a year ago; operating expenses rose to $90.5 million from $61.3 million on OCS Kidney, next-generation OCS and ENHANCE spending.

  • Full-Year Guidance Raised

    FY2026 revenue guidance lifted to $764-$774 million including about $14 million from PAD Aviation, from prior guidance of $737-$757 million excluding PAD, implying 26%-28% annual growth.

  • Two New FDA IDE Approvals

    In October the FDA approved IDE for ENHANCE Heart Part B and DENOVO Lung, and a continued access protocol allowing enrollment of 90 additional patients.


Analysis · TMDX · Industrial Applications And Services

The headline for a growth medtech still proving its margin story is the guidance raise, and TransMedics delivered it alongside its strongest quarter on record. Revenue of $203.0 million rose 41% (35% organic, excluding the newly acquired PAD Aviation), and net income swung back to $17.1 million after Q2's 58% profit decline. Profitability per share is the catch: diluted EPS fell to $0.46 from $0.66 a year ago as operating expenses climbed to $90.5 million on OCS Kidney, next-generation OCS and ENHANCE trial spending. Guidance now sits at $764-$774 million including roughly $14 million from PAD Aviation, up from $737-$757 million excluding it. Beyond the current liver and heart business, the growth runway extends through two new FDA IDE approvals (ENHANCE Heart Part B and DENOVO Lung) and a first European logistics tender in Italy.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TMDX was trading at $76.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $60.11 to $156.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TMDX - Latest Insights

TMDX
Nov 06, 2026, 2:06 PM EST
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $87.77
Real-time Price: $93.00 info
Change: +$5.23 (+6%) info
Market Cap: $3.266B info
TMDX
Nov 05, 2026, 4:10 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $82.50
Real-time Price: $93.00 info
Change: +$10.50 (+13%) info
Market Cap: $3.266B info
TMDX
Nov 05, 2026, 4:02 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $68.97
Real-time Price: $93.00 info
Change: +$24.03 (+35%) info
Market Cap: $3.266B info
TMDX
Aug 04, 2026, 4:44 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $88.04
Real-time Price: $93.00 info
Change: +$4.96 (+6%) info
Market Cap: $3.266B info
TMDX
Aug 04, 2026, 4:20 PM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $88.50
Real-time Price: $93.00 info
Change: +$4.50 (+5%) info
Market Cap: $3.266B info